
Bioengineering & Translational Medicine, Год журнала: 2025, Номер unknown
Опубликована: Май 22, 2025
Abstract Glioblastoma (GBM) is a highly malignant brain tumor with poor survival prognosis of 12–15 months despite current therapeutic strategies. Diagnosing GBM challenging, often requiring invasive techniques such as tissue biopsy and imaging methods that can provide inconclusive results. In this regard, liquid represents promising alternative, providing tumor‐derived information from less sources blood or cerebrospinal fluid. However, the typically low concentrations these biomarkers pose challenges for traditional detection techniques, limiting their sensitivity specificity. Recent advances in microfluidics offer potential solution by enhancing isolation cells molecules, thus improving detectability. This review discusses latest progress microfluidic‐based systems glioblastoma, laying basis future diagnostic practices are more accurate. As technologies evolve, they hold to transform diagnosis monitoring, ultimately patient outcomes.
Язык: Английский